Federal Register / Vol. 76, No. 33 / Thursday, February 17, 2011 / Notices 9355 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sooja K Kim, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6182, 

MSC 7892, Bethesda, MD 20892, (301) 435– 

1780, kims@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Neuropharmacology and Neuroplasticity. 

Date: March 10, 2011. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Carole L Jelsema, PhD, 

Chief and Scientific Review Officer, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4176, 

MSC 7850, Bethesda, MD 20892, (301) 435– 

1248, jelsemac@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflicts: Gastrointestinal Pathophysiology. 

Date: March 14, 2011. 

Time: 4 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Patricia Greenwel, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2178, 

MSC 7818, Bethesda, MD 20892, 301–435– 

1169, greenwep@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR09–129: 

MLPCN High Throughput Screening Assays 

for Drug Discovery. 

Date: March 15, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Ping Fan, MD, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5154, 

MSC 7840, Bethesda, MD 20892, 301–408– 

9971, fanp@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–10– 

180: CounterAct U 01. 

Date: March 15, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency, 300 Light Street, 

Baltimore, MD 21202. 

Contact Person: Jonathan K Ivins, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4040A, 

MSC 7806, Bethesda, MD 20892, (301) 594– 

1245, ivinsj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cancer Biology and Therapy. 

Date: March 15–16, 2011. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Eun Ah Cho, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6202, 

MSC 7804, Bethesda, MD 20892, (301) 451– 

4467, choe@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–10– 

276: Research Using Agriculturally Important 

Domestic Species. 

Date: March 21, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Michael Knecht, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6176, 

MSC 7892, Bethesda, MD 20892, (301) 435– 

1046, knechtm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Fellowship: 

Biophysical and Biochemical Sciences. 

Date: March 28–29, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Alexander Gubin, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4196, 

MSC 7812, Bethesda, MD 20892, 301–435– 

2902, gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RM10–015: 

Economics of Prevention. 

Date: March 29, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Kathy Salaita, SCD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3172, 

MSC 7770, Bethesda, MD 20892, 301–806– 

8250, salaitak@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Devices and Detection Systems. 

Date: March 29–30, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Georgetown Suites, 1000 29th Street, 

NW., Washington, DC 20007. 

Contact Person: Ross D. Shonat, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6172, 

MSC 7892, Bethesda, MD 20892, 301–435– 

2786, ross.shonat@nih.hhs.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RM10–016: 

Efficient Delivery of Effective Health Care. 

Date: March 30, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Kathy Salaita, SCD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3172, 

MSC 7770, Bethesda, MD 20892, 301–806– 

8250, salaitak@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Microbiology. 

Date: March 30, 2011. 

Time: 1:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Fouad A. El-Zaatari, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3206, 

MSC 7808, Bethesda, MD 20814–9692, (301) 

435–1149, elzaataf@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 11, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–3633 Filed 2–16–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, March 

7, 2011, 8 a.m. to March 8, 2011, 8 p.m., 

National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

which was published in the Federal 

Register on February 4, 2011, 76 FR 

6486–6487. 

The meeting will be held March 1, 

2011 to March 2, 2011. The meeting 

time and location remain the same. The 

meeting is closed to the public. 


jlentini on DSKJ8SOYB1PROD with NOTICES
9356 Federal Register / Vol. 76, No. 33 / Thursday, February 17, 2011 / Notices 

1TSA, ‘‘Transportation Sector-Specific Plan Mass 

Transit Modal Annex,’’ page 4 (May 2007). 

Dated: February 11, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–3632 Filed 2–16–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2) notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 552b(c) 

(4) and 552b(c) (6), Title 5 U.S.C., as 

amended. The purpose of this meeting 

is to evaluate requests for preclinical 

development resources, biologics, 

clinical assays and other developmental 

programs for potential new therapeutics 

for the treatment of cancer. The outcome 

of the evaluation will provide 

information to internal NCI committees 

that will decide whether NCI should 

support requests and make available 

contract resources for development of 

the potential therapeutic to improve the 

treatment of various forms of cancer. 

The research proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material and 

personal information concerning 

individuals associated with the 

proposed research projects, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, Clinical 

Assay Development Program (CADP). 

Date: March 4, 2011. 

Time: 9 a.m.–4 p.m. 

Agenda: To review grant applications for 

the CADP. 

Place: Bethesda Marriott North Hotel, 5701 

Marinelli Road, Bethesda, MD 20852. 

Contact Person: Dr. Barbara Conley, 

Executive Secretary, Clinical Assay 

Development Program (CADP), National 

Cancer Institute, NIH, 6130 Executive 

Boulevard, Room 6035A, Bethesda, MD 

20892. 301–496–8639. 

conleyba@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 10, 2011. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–3630 Filed 2–16–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

Intent To Request Approval From OMB 

of One New Public Collection of 

Information: Baseline Assessment for 

Security Enhancement (BASE) 

Program 

AGENCY: Transportation Security 

Administration, DHS. 

ACTION: 60-day notice. 

SUMMARY: The Transportation Security 

Administration (TSA) invites public 

comment on a new Information 

Collection Request (ICR) abstracted 

below that we will submit to the Office 

of Management and Budget (OMB) for 

approval in compliance with the 

Paperwork Reduction Act (PRA). The 

ICR describes the nature of the 

information collection and its expected 

burden. This voluntary collection 

allows TSA to conduct transportation 

security-related assessments during site 

visits with security and operating 

officials of transit agencies. 

DATES: Send your comments by April 

18, 2011. 

ADDRESSES: Comments may be emailed 

to TSAPRA@dhs.gov or delivered to the 

TSA PRA Officer, Office of Information 

Technology (OIT), TSA–11, 

Transportation Security Administration, 

601 South 12th Street, Arlington, VA 

20598–6011. 

FOR FURTHER INFORMATION CONTACT: 

Joanna Johnson at the above address, or 

by telephone (571) 227–3651. 

SUPPLEMENTARY INFORMATION: 

Comments Invited 

In accordance with the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501 

et seq.), an agency may not conduct or 

sponsor, and a person is not required to 

respond to, a collection of information 

unless it displays a valid OMB control 

number. The ICR documentation is 

available at http://www.reginfo.gov. 

Therefore, in preparation for OMB 

review and approval of the following 

information collection, TSA is soliciting 

comments to— 

(1) Evaluate whether the proposed 

information requirement is necessary for 

the proper performance of the functions 

of the agency, including whether the 

information will have practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including using 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Information Collection Requirement 

Purpose of Data Collection 

Approximately 6,000 transit service 

providers, commuter railroads, and long 

distance passenger railroad providers 

operate in the United States.1 Mass 

transit and passenger rail systems 

provide transportation services through 

buses, rail transit, long-distance rail, 

and other, less common types of service 

(cable cars, inclined planes, funiculars, 

and automated guideway systems). 

These systems can also include 

‘‘demand response services’’ for seniors 

and persons with disabilities, as well as 

vanpool/rideshare programs and taxi 

services operated under contract with a 

public transportation agency. 

TSA is required to ‘‘assess the security 

of each surface transportation mode and 

evaluate the effectiveness and efficiency 

of current Federal Government surface 

transportation security initiatives.’’ EO 

13416, section 3(a) (Dec. 5, 2006). While 

many transit systems have security and 

emergency response plans or protocols 

in place, no single database exists, nor 

is there a consistent approach to 

evaluating the extent to which security 

programs are in place across mass 

transit systems. 

TSA developed the Baseline 

Assessment for Security Enhancement 

(BASE) to evaluate the status of security 

and emergency response programs on 

transit systems throughout the nation. In 

particular, a BASE review assesses the 

security measures of mass transit and 

passenger rail systems and gathers data 

used by TSA to address its 

responsibilities, such as evaluating 

‘‘effectiveness and efficiency of current 

Federal Government surface 

transportation security initiatives’’ and 

developing modal specific annexes to 

the Transportation Systems Sector 

Specific Plan that include ‘‘an 

identification of existing security 


jlentini on DSKJ8SOYB1PROD with NOTICES